Ligand Pharmaceuticals Incorporated
corporate_fare Company Profile
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 32 items for LGND at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-30, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for LGND spans 10-Q, 8-K, 8-K/A.
Recent high-impact activity:
- Ligand 10-Q Details Q3 Loss, 51% Royalty Growth and $460M Notes Now Current
- Ligand Q3 Adjusted EPS Beats at $2.67 as Revenue Jumps 71.5% to $149M
- Ligand Q3 Royalties Up 51% to $70.3M, Raises 2026 Adjusted EPS Guidance
- Ligand Posts $1.43 Per-Share Q3 Loss as Royalty Story Faces First Test
- Ligand Commits Up to $47M to AvenCell for Royalty on Next-Gen CAR-T Pipeline
Financial Snapshot
Short Interest & Short Volume
10.53 days to coverFINRA reported short interest of 2,464,093 shares in LGND as of the October 30, 2026 settlement, a 1.5% decrease from the prior period — about 10.5 days to cover at its recent average daily volume. On November 20, 2026, 80.6% of LGND volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for LGND, detected from its recent SEC filings · based on capital-structure filings through 2026-06-25.
Upsized Convertible Notes Offering Closed · Favorable Conversion and Warrant Pricing
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Recent Capital Actions
-
2026-02-27 Proposed ATM Program $100M